|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
3
|
|
gptkbp:bfsParent
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:activities
|
Janus kinase inhibitor
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:baricitinib
|
|
gptkbp:clinical_trial
|
Phase 3
monotherapy or combination therapy
moderate to severe rheumatoid arthritis
RA-BEACON
RA-BEACON 2
RA-BEACON 3
|
|
gptkbp:contraindication
|
active infections
severe liver disease
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
oral tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Olumiant
|
|
gptkbp:ingredients
|
gptkb:baricitinib
C16 H17 N7 O2
|
|
gptkbp:interacts_with
|
live vaccines
other immunosuppressants
|
|
gptkbp:invention
|
2027
|
|
gptkbp:is_atype_of
|
L04 A A30
|
|
gptkbp:is_available_in
|
tablet form
various strengths
|
|
gptkbp:is_used_for
|
treatment of rheumatoid arthritis
|
|
gptkbp:lifespan
|
12 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:manufacturer
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:2018
gptkb:Australia
gptkb:Japan
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:pharmacokinetics
|
absorbed in gastrointestinal tract
|
|
gptkbp:population
|
adults
|
|
gptkbp:provides_information_on
|
EULAR guidelines
ACR guidelines
|
|
gptkbp:research_focus
|
efficacy in different populations
long-term safety
comparative effectiveness
|
|
gptkbp:safety_features
|
blood tests
liver function tests
lipid levels
|
|
gptkbp:side_effect
|
headache
nausea
gastrointestinal perforation
thrombosis
serious infections
increased liver enzymes
|
|
gptkbp:type_of_care
|
once daily dosing
treatment regimen flexibility
|